Display options
Cite
Yu D, Holm R, Goscinski MA, et al. Prognostic and clinicopathological significance of Cacna2d1 expression in epithelial ovarian cancers: a retrospective study. Am J Cancer Res. 2016;6(9):2088-2097
Yu, D., Holm, R., Goscinski, M. A., Trope, C. G., Nesland, J. M., & Suo, Z. (2016). Prognostic and clinicopathological significance of Cacna2d1 expression in epithelial ovarian cancers: a retrospective study. American journal of cancer research, 6(9), 2088-2097.
Yu, Dandan, et al. "Prognostic and clinicopathological significance of Cacna2d1 expression in epithelial ovarian cancers: a retrospective study." American journal of cancer research vol. 6,9 (2016): 2088-2097.
Yu D, Holm R, Goscinski MA, Trope CG, Nesland JM, Suo Z. Prognostic and clinicopathological significance of Cacna2d1 expression in epithelial ovarian cancers: a retrospective study. Am J Cancer Res. 2016 Sep 01;6(9):2088-2097. eCollection 2016. PMID: 27725913; PMCID: PMC5043117.
Copy Download .nbib Format: NLM
Share it on

Am J Cancer Res. 2016 Sep 01;6(9):2088-2097. eCollection 2016.

Prognostic and clinicopathological significance of Cacna2d1 expression in epithelial ovarian cancers: a retrospective study.

American journal of cancer research

Dandan Yu, Ruth Holm, Mariusz Adam Goscinski, Claes G Trope, Jahn M Nesland, Zhenhe Suo

Affiliations

  1. Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou UniversityHenan, China; Department of Pathology, The Norwegian Radium Hospital, Oslo University HospitalOslo 0424, Norway.
  2. Department of Pathology, The Norwegian Radium Hospital, Oslo University Hospital Oslo 0424, Norway.
  3. Department of Surgery, The Norwegian Radium Hospital, Oslo University Hospital Oslo 0424, Norway.
  4. Department of Gynaecology, The Norwegian Radium Hospital, Oslo University HospitalOslo 0424, Norway; Department of Gynaecology, Institute of Clinical Medicine, Faculty of Medicine, University of OsloOslo 0379, Norway.
  5. Department of Pathology, The Norwegian Radium Hospital, Oslo University HospitalOslo 0424, Norway; Department of Pathology, Institute of Clinical Medicine, Faculty of Medicine, University of OsloOslo 0379, Norway.
  6. Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou UniversityHenan, China; Department of Pathology, The Norwegian Radium Hospital, Oslo University HospitalOslo 0424, Norway; Department of Pathology, Institute of Clinical Medicine, Faculty of Medicine, University of OsloOslo 0379, Norway.

PMID: 27725913 PMCID: PMC5043117

Abstract

Ovarian cancer is the most lethal gynecologic malignancy, in which cancer stem cells (CSC) have been reported to be the driving force of relapse and therapy-resistance. It is therefore important to explore CSC markers in ovarian cancer. This project aimed to explore the correlation between the expression of potential CSC maker Cacna2d1 and clinicopathological parameters in 238 epithelial ovarian cancer (EOC) samples. Immunohistochemically, positive Cacna2d1 expression was observed in 83.6% (199/238) of the EOC tumors, among which 107 tumors (44.9%) were highly positive and 92 (38.7%) tumors were weakly positive for the Cacna2d1 protein expression. Among the 158 serous carcinomas, the Cacna2d1 positivity was 148 (93.7%), in which 88 (55.7%) were highly positive, and 60 (38.0%) were weakly positive for the Cacna2d1 protein expression. Most strikingly, the Cacna2d1 was specifically expressed in the infiltration front areas of the EOC tumors. Statistical analyses showed that positive expression of Cacna2d1 was significantly associated with advanced FIGO stage (

Keywords: Cacna2d1; Ovarian carcinoma; cancer stem cell; immunohistochemistry; molecular pathology

References

  1. Jpn J Radiol. 2016 Feb;34(2):117-24 - PubMed
  2. Gene. 2014 Aug 15;547(1):43-9 - PubMed
  3. Eur J Hum Genet. 2015 May;23(5):628-32 - PubMed
  4. Cancer Res. 2014 Sep 1;74(17):4922-36 - PubMed
  5. Reproduction. 2015 Feb;149(2):R59-70 - PubMed
  6. Biomark Cancer. 2016 Mar 16;8:43-56 - PubMed
  7. BMC Cancer. 2015 Jul 07;15:502 - PubMed
  8. FEBS Lett. 1996 Nov 18;397(2-3):331-7 - PubMed
  9. Gynecol Oncol. 2016 Jul;142(1):199-205 - PubMed
  10. Cardiol Young. 2015 Jan;25(1):174-6 - PubMed
  11. Clin Cancer Res. 2016 Sep 15;22(18):4664-75 - PubMed
  12. Mol Clin Oncol. 2016 Jan;4(1):18-22 - PubMed
  13. N Engl J Med. 2016 Feb 25;374(8):738-48 - PubMed
  14. J Clin Oncol. 2016 Jul 1;34(19):2271-8 - PubMed
  15. Curr Protein Pept Sci. 2015;16(4):270-8 - PubMed
  16. Am J Transl Res. 2015 May 15;7(5):841-55 - PubMed
  17. Nat Rev Neurosci. 2012 Jul 18;13(8):542-55 - PubMed
  18. Nat Commun. 2015 Sep 30;6:8271 - PubMed
  19. J Vis Exp. 2014 Sep 10;(91):51891 - PubMed
  20. Gynecol Oncol. 2010 Mar;116(3):351-7 - PubMed
  21. Sci Rep. 2015 May 28;5:10357 - PubMed
  22. J Comp Neurol. 2005 Oct 24;491(3):246-69 - PubMed
  23. J Clin Pathol. 1986 Dec;39(12):1340-6 - PubMed
  24. Gynecol Oncol. 2016 Jul;142(1):184-9 - PubMed
  25. AJR Am J Roentgenol. 2016 Jun;206(6):1351-60 - PubMed
  26. Onco Targets Ther. 2013 Jul 24;6:967-76 - PubMed
  27. Mol Med Rep. 2015 Feb;11(2):1334-9 - PubMed
  28. CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30 - PubMed
  29. J Neurosci. 2009 Apr 1;29(13):4076-88 - PubMed
  30. Indian J Surg Oncol. 2016 Jun;7(2):188-97 - PubMed

Publication Types